4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
FDMT on Nasdaq
Shares outstanding
57,042,766
Price per share
$8.97
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
53,385,790
Total reported value
$400,382,704
% of total 13F portfolios
0%
Share change
+14,042,649
Value change
+$105,177,856
Number of holders
148
Price from insider filings
$8.97
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 10% 0% $45,959,629 +$9,546,222 5,847,281 +26% BVF PARTNERS L P/IL 31 Dec 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $44,910,877 +$9,031,022 5,713,852 +25% RA Capital Management, L.P. 31 Dec 2025
JANUS HENDERSON GROUP PLC 8.1% +64% $36,437,978 +$18,735,371 4,635,875 +106% JANUS HENDERSON GROUP PLC 31 Dec 2025
GOLDMAN SACHS GROUP INC 7.5% -21% $33,688,569 -$1,079,634 4,286,077 -3.1% THE GOLDMAN SACHS GROUP, INC. 31 Dec 2025
Novo Holdings A/S 6.4% -5.7% $28,694,793 +$3,739,293 3,650,737 +15% Novo Holdings A/S 31 Dec 2025
BlackRock, Inc. 6.6% -15% $26,613,959 -$4,803,137 3,062,596 -15% BlackRock, Inc. 30 Sep 2025
Venrock Healthcare Capital Partners III, L.P. 1.5% -82% $2,202,200 -$7,393,006 677,600 -77% Venrock Healthcare Capital Partners III, L.P. 31 Mar 2025
Deep Track Capital, LP 1.3% $1,982,175 609,900 Deep Track Capital, LP 31 Dec 2024

As of 31 Dec 2025, 148 institutional investors reported holding 53,385,790 shares of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT). This represents 94% of the company’s total 57,042,766 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 9.9% 5,653,211 +24% 0.44% $42,399,083
JANUS HENDERSON GROUP PLC 8.1% 4,635,875 +164% 0.02% $34,726,165
BVF INC/IL 8.1% 4,629,289 0% 1.2% $34,719,668
GOLDMAN SACHS GROUP INC 7.5% 4,302,905 +4.2% 0% $32,271,789
BlackRock, Inc. 7.1% 4,064,876 +5.1% 0% $30,486,573
NOVO HOLDINGS A/S 6.4% 3,650,737 +83% 2.1% $27,380,528
VANGUARD GROUP INC 5.4% 3,093,527 +20% 0% $23,201,453
STATE STREET CORP 4.7% 2,688,880 +198% 0% $20,166,600
ARMISTICE CAPITAL, LLC 3.4% 1,936,000 +77% 0.36% $14,520,000
FEDERATED HERMES, INC. 2.8% 1,609,482 +0.92% 0.02% $12,071,116
Point72 Asset Management, L.P. 2.7% 1,539,860 0.02% $11,548,950
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.2% 1,235,156 +606% 0.01% $9,263,670
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,012,025 +11% 0% $7,591,665
Evergreen Quality Fund GP, Ltd. 1.7% 951,474 0.14% $7,136,055
BANK OF AMERICA CORP /DE/ 1.5% 832,591 +1.6% 0% $6,244,433
DEUTSCHE BANK AG\ 1.2% 704,207 +30% 0% $5,281,553
MORGAN STANLEY 1.2% 672,695 -20% 0% $5,045,215
RENAISSANCE TECHNOLOGIES LLC 0.9% 512,900 +64% 0.01% $3,846,750
Parkman Healthcare Partners LLC 0.88% 503,431 +152% 0.36% $3,775,733
ArrowMark Colorado Holdings LLC 0.85% 485,389 -3.7% 0.08% $3,640,418
RAYMOND JAMES FINANCIAL INC 0.84% 477,505 +1.3% 0% $3,581,288
RTW INVESTMENTS, LP 0.83% 475,737 0.04% $3,568,028
BAKER BROS. ADVISORS LP 0.83% 475,737 0.02% $3,568,028
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.62% 353,391 +16% 0% $2,650,433
TWO SIGMA INVESTMENTS, LP 0.59% 337,503 +23% 0% $2,531,273

Institutional Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 53,385,790 $400,382,704 +$105,177,856 $7.50 148
2025 Q3 39,480,388 $343,063,699 -$4,201,365 $8.69 129
2025 Q2 40,369,426 $149,859,289 -$9,235,482 $3.71 117
2025 Q1 43,058,381 $139,823,044 -$22,403,324 $3.23 122
2024 Q4 46,814,824 $260,642,119 -$79,332,651 $5.57 140
2024 Q3 57,948,767 $626,374,639 -$34,446,524 $10.81 135
2024 Q2 57,307,189 $1,203,018,791 +$3,520,347 $20.99 138
2024 Q1 56,228,706 $1,790,823,856 +$449,592,828 $31.86 146
2023 Q4 42,433,937 $859,819,319 +$24,792,782 $20.26 111
2023 Q3 41,913,779 $533,559,212 +$5,221,810 $12.73 110
2023 Q2 41,248,927 $745,334,512 +$197,052,931 $18.07 100
2023 Q1 30,404,028 $522,337,328 +$34,968,755 $17.19 94
2022 Q4 28,011,571 $622,110,124 +$47,681,640 $22.21 97
2022 Q3 26,181,987 $210,496,945 +$1,974,268 $8.04 84
2022 Q2 26,027,061 $181,670,139 -$2,172,042 $6.98 86
2022 Q1 26,134,053 $395,189,957 +$20,420,485 $15.12 76
2021 Q4 24,702,968 $541,790,297 +$81,054,878 $21.94 77
2021 Q3 18,711,908 $504,667,012 +$57,523,278 $26.97 61
2021 Q2 16,612,608 $400,026,000 +$731,531 $24.08 54
2021 Q1 15,384,514 $664,816,567 +$34,097,345 $43.38 63
2020 Q4 14,593,004 $602,432,000 +$578,482,000 $41.45 51